Français
ItalianoBond Celgen Corporation 3.875% ( US151020AS39 ) in USD
| Issuer | Celgen Corporation |
| Market price | 102.101 % ⇌ |
| Country |  United States
|
| ISIN code |
 US151020AS39 ( in USD )
|
| Interest rate | 3.875% per year ( payment 2 times a year) |
| Maturity | 14/08/2025 - Bond has expired |
|
Prospectus brochure in PDF format is unavailable at this time We will provide it as soon as possible |
|
| Minimal amount | 2 000 USD |
| Total amount | 2 500 000 000 USD |
| Cusip | 151020AS3 |
| Standard & Poor's ( S&P ) rating | A+ ( Upper medium grade - Investment-grade ) |
| Moody's rating | N/A |
| Detailed description |
Celgene Corporation was a biopharmaceutical company acquired by Bristol Myers Squibb in 2019, known for its development and commercialization of cancer therapies and other immunology treatments. Celgene Corp. issued a USD 2,500,000,000 bond (ISIN: US151020AS39, CUSIP: 151020AS3) maturing August 14, 2025, with a 3.875% coupon rate, paying semi-annually, currently trading at 102.101%, minimum purchase 2000, rated A+ by S&P. |